Andrew Schiermeier, AvenCell Therapeutics CEO
October 22, 2024 06:00 AM EDTUpdated 06:29 AM
Financing
Cell/Gene Tx

Aven­Cell gets $112M to build switch­able CAR-T ther­a­pies for ‘the last fron­tier’ of blood can­cers

Lei Lei Wu

News Reporter

Aven­Cell Ther­a­peu­tics on Tues­day said it col­lect­ed $112 mil­lion to con­tin­ue clin­i­cal stud­ies of two ex­per­i­men­tal acute myeloid leukemia CAR-T cell ther­a­pies.

The Se­ries B …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Roche, Genen­tech end an­ti-tau Alzheimer’s drug col­lab­o­ra­tion with UCB

No­vo de­clares Phase 3 car­diac out­comes tri­al win for oral GLP-1

Star­board takes ac­tivist stake in J&J con­sumer spin­out Ken­vue

FDA hits Ca­mu­rus with CRL for acromegaly ther­a­py over man­u­fac­tur­ing is­sues 

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times